Azurity Loses Hypertension Drug Patent Trial Against Alkem
By Ryan Davis · February 13, 2023, 10:00 PM EST
A federal judge sitting in Delaware ruled Friday that several claims of two patents on Azurity Pharmaceuticals Inc.'s hypertension drug Epaned are invalid, handing a win to Alkem Laboratories Ltd., which...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login